RCKT
NASDAQ · Biotechnology
Rocket Pharmaceuticals Inc
$2.47
+0.03 (+1.23%)
Open$2.45
Previous Close$2.44
Day High$2.50
Day Low$2.41
52W High$5.45
52W Low$2.17
Volume—
Avg Volume1.83M
Market Cap260.71M
P/E Ratio—
EPS$-0.18
SectorBiotechnology
Analyst Ratings
Buy
20 analysts
Price Target
+583.0% upside
Current
$2.47
$2.47
Target
$16.87
$16.87
$13.87
$16.87 avg
$23.44
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 67.67M | 66.73M | 71.52M |
| Net Income | -17,020,193 | -15,934,880 | -16,470,876 |
| Profit Margin | -25.2% | -23.9% | -23.0% |
| EBITDA | -23,292,743 | -22,716,839 | -22,207,941 |
| Free Cash Flow | -11,691,320 | -15,075,459 | -16,131,538 |
| Rev Growth | +1.5% | +16.6% | +10.7% |
| Debt/Equity | 1.36 | 1.21 | 1.30 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.34 | +1.08% | 81.4 | 513.86B |
| AMGN | Amgen Inc | $461.10 | +0.18% | 28.5 | 249.09B |
| GILD | Gilead Sciences Inc | $168.18 | +0.36% | — | 212.04B |
| VRTX | Vertex Pharmaceuticals Inc | $546.92 | +0.81% | 30.6 | 134.77B |
| REGN | Regeneron Pharmaceuticals | $908.12 | +0.58% | 19.5 | 84.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $157.53 | +0.56% | 28.8 | 23.28B |